Your browser doesn't support javascript.
loading
Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.
Tourigny, David S; Zucker, Mark; Kim, Minsoo; Russo, Paul; Coleman, Jonathan; Lee, Chung-Han; Carlo, Maria I; Chen, Ying-Bei; Hakimi, A Ari; Kotecha, Ritesh R; Reznik, Ed.
Affiliation
  • Tourigny DS; Irving Institute for Cancer Dynamics, Columbia University, New York, NY, United States.
  • Zucker M; School of Mathematics, University of Birmingham, Birmingham, United Kingdom.
  • Kim M; Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Russo P; Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Coleman J; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Lee CH; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Carlo MI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Chen YB; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Hakimi AA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Kotecha RR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Reznik E; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Front Oncol ; 12: 910147, 2022.
Article in En | MEDLINE | ID: mdl-35837094
ABSTRACT
Renal medullary carcinoma (RMC) is a highly aggressive disease associated with sickle hemoglobinopathies and universal loss of the tumor suppressor gene SMARCB1. RMC has a relatively low rate of incidence compared with other renal cell carcinomas (RCCs) that has hitherto made molecular profiling difficult. To probe this rare disease in detail we performed an in-depth characterization of the RMC tumor microenvironment using a combination of genomic, metabolic and single-cell RNA-sequencing experiments on tissue from a representative untreated RMC patient, complemented by retrospective analyses of archival tissue and existing published data. Our study of the tumor identifies a heterogenous population of malignant cell states originating from the thick ascending limb of the Loop of Henle within the renal medulla. Transformed RMC cells displayed the hallmarks of increased resistance to cell death by ferroptosis and proteotoxic stress driven by MYC-induced proliferative signals. Specifically, genomic characterization of RMC tumors provides substantiating evidence for the recently proposed dependence of SMARCB1-difficient cancers on proteostasis modulated by an intact CDKN2A-p53 pathway. We also provide evidence that increased cystine-mTORC-GPX4 signaling plays a role in protecting transformed RMC cells against ferroptosis. We further propose that RMC has an immune landscape comparable to that of untreated RCCs, including heterogenous expression of the immune ligand CD70 within a sub-population of tumor cells. The latter could provide an immune-modulatory role that serves as a viable candidate for therapeutic targeting.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Type: Article Affiliation country: United States